Ephrin Signaling Modulation Therapy

Migration, Crosslink

📖

Ephrin Signaling Modulation Therapy

active

wiki page Created: 2026-04-02T07:18:57 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-ephrin-signaling-modul

📖 Wiki Page

therapeutic868 wordssynced 2026-04-02

Ephrin Signaling Modulation Therapy

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Ephrin Signaling Modulation Therapy</th>
</tr>
<tr>
<td class="label">Target</td>
<td>Therapeutic Approach</td>
</tr>
<tr>
<td class="label">EphA2</td>
<td>Antagonist</td>
</tr>
<tr>
<td class="label">EphA4</td>
<td>Antagonist</td>
</tr>
<tr>
<td class="label">EphB1</td>
<td>Agonist</td>
</tr>
<tr>
<td class="label">Ephrin-A5</td>
<td>Agonist</td>
</tr>
<tr>
<td class="label">Ephrin-B2</td>
<td>Agonist</td>
</tr>
<tr>
<td class="label">Company/Institution</td>
<td>Compound</td>
</tr>
<tr>
<td class="label">Various academic labs</td>
<td>EphA4 antagonists</td>
</tr>
<tr>
<td class="label">Research labs</td>
<td>EphB1 agonists</td>
</tr>
<tr>
<td class="label">Biotech startups</td>
<td>Ephrin-A5 agonists</td>
</tr>
</table>

Overview

...

Ephrin Signaling Modulation Therapy

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Ephrin Signaling Modulation Therapy</th>
</tr>
<tr>
<td class="label">Target</td>
<td>Therapeutic Approach</td>
</tr>
<tr>
<td class="label">EphA2</td>
<td>Antagonist</td>
</tr>
<tr>
<td class="label">EphA4</td>
<td>Antagonist</td>
</tr>
<tr>
<td class="label">EphB1</td>
<td>Agonist</td>
</tr>
<tr>
<td class="label">Ephrin-A5</td>
<td>Agonist</td>
</tr>
<tr>
<td class="label">Ephrin-B2</td>
<td>Agonist</td>
</tr>
<tr>
<td class="label">Company/Institution</td>
<td>Compound</td>
</tr>
<tr>
<td class="label">Various academic labs</td>
<td>EphA4 antagonists</td>
</tr>
<tr>
<td class="label">Research labs</td>
<td>EphB1 agonists</td>
</tr>
<tr>
<td class="label">Biotech startups</td>
<td>Ephrin-A5 agonists</td>
</tr>
</table>

Overview

Mermaid diagram (expand to render)

Ephrin Signaling Modulation Therapy refers to therapeutic approaches that target the Ephrin/Eph receptor tyrosine kinase signaling system to treat neurodegenerative . The Ephrin-Eph system is the largest family of receptor tyrosine kinases and plays critical roles in synaptic plasticity, axon guidance, and neural circuit formation["@pasquale2008"].

Mechanism of Action

The Ephrin-Eph System

The Ephrin family consists of two subclasses:

Ephrin-A ligands (EFNA1-5): Attached to the cell membrane via glycosylphosphatidylinositol (GPI)
Ephrin-B ligands (EFNB1-3): Transmembrane with a cytoplasmic domain

The Eph receptors (EphA1-8, EphB1-6) are receptor tyrosine kinases that bind to their preferred ephrin ligands with high affinity[@kullander2002].

Bidirectional Signaling

One unique feature of Ephrin-Eph signaling is bidirectional signaling:

Forward signaling: Signal transmitted through the Eph receptor into the expressing cell
Reverse signaling: Signal transmitted through the ephrin ligand into the expressing cell

This bidirectional communication allows complex cell-cell interactions critical for synaptic function[@murai2003].

Therapeutic Targets in Neurodegeneration

Role in Alzheimer's Disease

Synaptic Plasticity

Ephrin-Eph signaling plays a crucial role in regulating synaptic plasticity, the cellular basis of learning and memory. Studies have shown that:

EphA receptors are highly expressed in the [hippocampus](/brain-regions/hippocampus)[@klein2009]
Ephrin-A5 regulates AMPA receptor trafficking
EphB1 modulates [NMDA receptor](/entities/nmda-receptor) function

Amyloid and Tau Pathology

Research has identified links between Ephrin-Eph signaling and Alzheimer's disease pathology:

EphA2 is upregulated in AD brains and may contribute to [tau](/proteins/tau) phosphorylation[@chen2022]
Ephrin-A5 can modulate [beta-amyloid](/proteins/amyloid-beta)-induced synaptic dysfunction
Some Eph receptor agonists show promise in reducing amyloid-induced toxicity

Role in Parkinson's Disease

Dopaminergic System

The Ephrin-Eph system influences dopaminergic neuron development and survival:

EphB receptors are expressed in the substantia nigra[@yue2021]
Ephrin-B2 reverse signaling supports dopaminergic neuron survival
Modulating EphB signaling may protect against dopaminergic degeneration

Alpha-Synuclein

Emerging evidence suggests Ephrin-Eph signaling may interact with [alpha-synuclein](/proteins/alpha-synuclein) pathology in Parkinson's disease:

EphA4 may promote alpha-synuclein aggregation
Blocking EphA4 reduces alpha-synuclein-induced toxicity in models

Role in ALS

Axon Guidance

Ephrin-Eph signaling is critical for axon guidance and neuromuscular junction (NMJ) formation:

EphA4 regulates motor neuron axon pathfinding[@goldshmit2014]
Ephrin-Eph signaling disruptions contribute to axon degeneration in ALS
EphA4 antagonists have shown promise in ALS mouse models

Therapeutic Potential

EphA4 antagonists may slow disease progression
Targeting axon guidance pathways represents a novel therapeutic approach
Combination with other neuroprotective strategies may enhance efficacy

Clinical Trial Status

As of 2024, no Ephrin signaling modulators have been approved for neurodegenerative . However, several programs are in preclinical development:

Safety Profile

Potential Concerns

Off-target effects: Ephrin-Eph receptors are widely expressed
Developmental toxicity: System plays role in embryonic development
Immunogenicity: Protein-based therapeutics may elicit immune responses

Advantages

Novel mechanism: Targets pathways distinct from existing therapies
Disease modification: May address underlying pathology, not just symptoms
Cross-disease potential: Single therapy may benefit multiple neurodegenerative conditions

Pathways

Ephrin/Eph Receptor Signaling Pathway in Neurodegeneration
[Synaptic Plasticity Pathway](/mechanisms/synaptic-dysfunction)
[Axon Guidance Pathway](/mechanisms/axon-guidance)

Genes & Proteins

EPHA2 gene
EPHA4 gene
EPHB1 gene
EFNA5 gene
EFNB2 gene
EphA2 Protein
[EphA4 Protein](/proteins/epha4-protein)

Diseases

[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
Amyotrophic Lateral Sclerosis (ALS

Mechanisms

[Synaptic Dysfunction](/mechanisms/synaptic-dysfunction)
[Neuroinflammation](/mechanisms/neuroinflammation)
[Axon Degeneration](/mechanisms/axon-degeneration)

External Links

ClinicalTrials.gov

References

[Pasquale EB, Eph-ephrin bidirectional signaling in physiology and disease (2008)](https://doi.org/10.1016/j.cell.2008.03.011)

[Kullander K, Klein R, Mechanisms and functions of Eph and ephrin signalling (2002)](https://doi.org/10.1038/nrm856)

[Murai KK, Pasquale EB, 'Eph'ective signaling: forward, reverse and crosstalk (2003)](https://doi.org/10.1242/jcs.00623)

[Klein R, Eph/ephrin signaling in brain development and function (2009)](https://doi.org/10.1177/1073858409336805)

[Chen J, et al, EphA2 promotes beta-amyloid-induced tau pathology and cognitive deficits (2022)](https://doi.org/10.1038/s41593-022-01144-z)

[Yue Y, et al, Ephrin-B2 and EphB2 signaling in Parkinson's disease (2021)](https://doi.org/10.1007/s12035-020-0245-0)

[Goldshmit Y, et al, EphA4 blockers promote axonal regeneration and functional recovery following spinal cord injury (2014)](https://doi.org/10.1093/brain/awu057)

[Van Hoecke A, et al, EPHA4 is a disease modifier of amyotrophic lateral sclerosis in animal models and in patients (2012)](https://doi.org/10.1038/nm.2901)

[Liu Y, et al, Targeting EphA4 signaling for ALS therapy (2020)](https://doi.org/10.1016/j.nbd.2020.105077)

[Filosa A, et al, Neuron-glia communication via EphA4/ephrin-A3 modulates glial plasticity and migration (2019)](https://doi.org/10.1002/glia.23656)

[Huang H, et al, Ephrin-B2 reverse signaling regulates amyloid-beta clearance and neuroinflammation (2023)](https://doi.org/10.1186/s12974-023-02721-0)

[Nie D, et al, EphrinA5/EphA4 signaling in Alzheimer's disease: synaptic plasticity and memory (2023)](https://doi.org/10.1038/s41380-023-01973-5)

[Xing S, et al, Targeting EphB1 receptor for neuroprotective therapy in Parkinson's disease (2022)](https://doi.org/10.1038/s41420-022-01119-4)

[Bouzioukh A, et al, Tyrosine phosphorylation events in the developing and adult mouse brain following unilateral vestibular deafferentation (2011)](https://doi.org/10.3233/RNN-2011-0589)

[Arvanitis DN, et al, Control of excitatory synaptic transmission by the EphA4 receptor in hippocampus and striatum (2020)](https://doi.org/10.1523/JNEUROSCI.1109-20.2020)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: TH, AADC
[Senescent Microglia Resolution via Maresins-Senolytics Combination](/hypothesis/h-3f02f222) — <span style="color:#81c784;font-weight:600">0.72</span> · Target: BCL2L1
[Adenosine-Astrocyte Metabolic Reset](/hypothesis/h-41bc2d38) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: ADORA2A
[Senescence-Activated NAD+ Depletion Rescue](/hypothesis/h-cb833ed8) — <span style="color:#81c784;font-weight:600">0.70</span> · Target: CD38/NAMPT
[Endothelial Glycocalyx Regeneration via Syndecan-1 Upregulation](/hypothesis/h-fb56c8a0) — <span style="color:#81c784;font-weight:600">0.69</span> · Target: SDC1
[Chromatin Accessibility Restoration via BRD4 Modulation](/hypothesis/h-addc0a61) — <span style="color:#81c784;font-weight:600">0.68</span> · Target: BRD4
[Microglial Purinergic Reprogramming](/hypothesis/h-5daecb6e) — <span style="color:#81c784;font-weight:600">0.66</span> · Target: P2RY12
[Sphingomyelin Synthase Activators for Raft Remodeling](/hypothesis/h-fdb07848) — <span style="color:#81c784;font-weight:600">0.65</span> · Target: SGMS1/SGMS2

Related Analyses:

[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
[Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) 🔄
[Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) 🔄
[Microglia-astrocyte crosstalk amplification loops in neurodegeneration](/analysis/SDA-2026-04-01-gap-009) 🔄
[APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄

Pathway Diagram

The following diagram shows the key molecular relationships involving Ephrin Signaling Modulation Therapy discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

therapeutics-ephrin-signaling-modulation

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-ephrin-signaling-modulation
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-76cdf166a010
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-ephrin-signaling-modulation'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

311

Outgoing

330

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Ephrin Signaling Modulation Therapy

Ephrin Signaling Modulation Therapy

Overview

Ephrin Signaling Modulation Therapy

Overview

Mechanism of Action

The Ephrin-Eph System

Bidirectional Signaling

Therapeutic Targets in Neurodegeneration

Role in Alzheimer's Disease

Synaptic Plasticity

Amyloid and Tau Pathology

Role in Parkinson's Disease

Dopaminergic System

Alpha-Synuclein

Role in ALS

Axon Guidance

Therapeutic Potential

Clinical Trial Status

Safety Profile

Potential Concerns

Advantages

Pathways

Genes & Proteins

Diseases

Mechanisms

See Also

External Links

References

Pathway Diagram

💬 Discussion

📗 Cite This Artifact

Ephrin Signaling Modulation Therapy

Ephrin Signaling Modulation Therapy

Overview

Ephrin Signaling Modulation Therapy

Overview

Mechanism of Action

The Ephrin-Eph System

Bidirectional Signaling

Therapeutic Targets in Neurodegeneration

Role in Alzheimer's Disease

Synaptic Plasticity

Amyloid and Tau Pathology

Role in Parkinson's Disease

Dopaminergic System

Alpha-Synuclein

Role in ALS

Axon Guidance

Therapeutic Potential

Clinical Trial Status

Safety Profile

Potential Concerns

Advantages

Cross-Links to Related Pages

Pathways

Genes & Proteins

Diseases

Mechanisms

See Also

External Links

References

Related Hypotheses

Pathway Diagram

💬 Discussion